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• Bone metastases cause skeletal-related events (SREs) or bone complications, commonly defined as radiation to bone, pathologic fracture, surgery to bone and spinal cord compression -SREs place a substantial burden on both patients and healthcare systems
• Patients experience a reduction in quality of life, notably with reductions in physical and functional well-being. Patients often report considerable pain which also further impairs mobility and quality of life [4] [5] [6] -SREs also require a substantial amount of management, often including inpatient stays, which further drives resource use and associated costs [7] [8] [9] [10] • Historically, the bisphosphonate zoledronic acid has been standard of care across many countries in Europe
• In a head-to-head trial denosumab, a fully human monoclonal antibody against RANKL, was superior to zoledronic acid in delaying the first SRE ( 
OBJECTIVES
• To estimate the total number of SREs, associated hospital burden and direct medical costs avoided when denosumab is used instead of zoledronic acid for the prevention of SREs in patients with prostate cancer and bone metastases from Austria, the Czech Republic, Germany, Greece, Italy, Spain and Switzerland
METHODS
Prevalence of bone metastatic advanced prostate cancer -Average survival was 3-5 years for patients with advanced prostate cancer -Assuming a constant rate and an exponential distrubution of survival times, the average survival of patients with advanced prostate cancer was calculated as the inverse of the annual mortality rate
RESULTS

Prevalence of patients with bone metastases and SREs
• Estimated prevalence by country of the 66,376 patients with advanced prostate cancer and bone metastases is presented in Table 2 • From the Fizazi et al. study, 17 radiation to bone was the most common SRE accounting for 66% of the total 1,723 SREs, followed by pathologic fracture 27% of the total events. Surgery to bone was the least common event, accounting for only 1% of SREs
• If denosumab was the selected treatment option for all patients, an estimated 38,690
SREs could be avoided per year compared with using zoledronic acid for all patients, which is equivalent to a 21% reduction (Figure 1) -Denosumab reduced the number of SREs in all seven countries
• Proportions of SREs avoided across countries were consistent although absolute numbers differed given the variation in patient population size between countries -In Germany, 16,582 SREs were avoided, in Italy this figure was 9,724 SREs -Smaller absolute reductions were observed in Austria where 1,426 SREs were avoided in a patient population of 2,447 men with prostate cancer and bone metastases
LIMITATIONS
• Only cost savings directly associated with hospital care were considered in this analysis therefore, wider economic savings such as those associated with treatment administration, hospital transportation and at home care can also be expected
• Costs of zoledronic acid and denosumab were not considered in this analysis, particularly for denosumab, some cost savings may be off-set by the price of the drug
• Comparisons between outcomes in the different countries should be interpreted with caution as they also reflect differences in clinical practice
CONCLUSIONS
• For all countries included in this analysis, when denosumab was the selected treatment option, all variables (number of SREs, number of hospitalisations per SRE and required days in hospital) were reduced by 21% 
SRE rates
• Data from an European observational study 7 conducted in Germany, Italy, Spain, and the United Kingdom were combined with the treatment effect of denosumab versus zoledronic acid reported in two head-to-head clinical trials 17, 18 to predict the total number of SREs by treatment type -SRE rates were estimated by dividing the total number of SREs by the number of patient years on study 7, 17 -To ensure the model better reflected SRE rates observed in clinical practice, a rate ratio of 2.9 was applied to the rate of events in both treatment arms, ensuring alignment between the clinical predictions and real-world outcomes observed in patients receiving zoledronic acid
Resource use and associated costs
• A total reduction in hospitalisations per SRE was observed for all countries with a total of 14,599 hospitalisations avoided, equivalent to a 21% reduction (Figure 1) -The largest reduction was seen in Germany (5,024 hospitalisations avoided) and the smallest in the Czech Republic (1,003 avoided)
• Reductions in incidence of SREs and associated healthcare resource use when denosumab was used instead of zoledronic acid results in an estimated total cost saving of €155.2 million, equivalent to a 21% reduction (Figure 3) -Largest cost savings were in Germany and Switzerland -The smallest difference in cost saving was in the Czech Republic
• For patients requiring an inpatient stay, using denosumab versus zoledronic acid was associated with a reduction in the number of days spent in hospital per SRE in all countries -This equated to an overall total of 270,007 hospital days saved, or a 21% reduction (Figure 2) -Largest savings were observed in Germany (98,166 days) and Italy (71,387 days), the smallest reduction was seen in Greece (12,210 days saved) • A model was developed to predict, in each country:
-The number of patients with prostate cancer and bone metastases -Annual SRE rates to estimate the total number of predicted SREs by treatment option -The number of SREs in each country, in patients with prostate cancer and bone metastases, if all of these patients would be treated with denosumab or zoledronic acid
• The following inputs were included -The prevalence of prostate cancer with bone metastases assuming a steady state approach -Annual SRE rates from an European observational study and the treatment effect observed in a head-to-head clinical trial of denosumab versus zoledronic acid were used to estimate the total number of predicted SREs by treatment option -Country-specific findings from two retrospective studies were used to estimate the total number of hospitalisations, inpatient days and direct medical costs associated with the management of SREs
Resource use and direct medical costs of managing SREs
• Country-specific data for hospitalisation rates, duration of inpatient stays, and the associated direct medical costs were taken from two observational resource-use studies (Table 1) 7,19 
